MediGene AG


Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ----------------------------------------------------

    Munich (ots Ad hoc-Service) -      
    MediGene AG announces the start of a phase 3 trial for Polyphenon
(TM) E to treat genital warts

    The German biopharmaceutical company MediGene AG, Munich, (NMarkt:MDG), announced today that a phase 3 trial for Polyphenon(TM) E to treat genital warts caused by Human Papilloma Viruses was initiated in the last week of December 2000. MediGene currently has three product candidates in clinical trials in- cluding two in advanced trials: Etomoxir against congestive heart failure in phase 2 and Polyphenon (TM) E against genital warts in phase 3. Internal development and the planned acquisition of NeuroVir Inc. are to add another three product candidates in clinical trials to the clinical pipeline in the first quarter of 2001.

    The major aim of the study will be to test the efficacy of two different formulations of Polyphenon (TM) E for the treatment of external genital warts. Phase 1 and 2 clinical trials performed for Polyphenon (TM) E in Canada, the USA and China have demonstrated safety and a positive trend in efficacy.

    Genital warts are tumors caused by the virus strains HPV 6 and HPV 11. The tumors are non-malignant, but disfigure the genital tract and can be painful. Genital warts are one of the fastest growing sexually transmitted diseases worldwide. 14 million people in North America and Europe suffer from the disease, of which only about 3 million are seeking treatment today.


    This ad hoc release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward looking statements are no guarantees for future performance, and the forward-looking events discussed in this ad hoc release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements.

    For further information please contact:

    MediGene AG email: fax: ++49 -89-89 56 32-20

    Christine Bohner, Public Relations phone: ++49 - 89 - 89 56 32-16 Michael Nettersheim, Investor Relations phone: ++49 - 89 - 89 56 32-46

End ----------------------------------------------------- Internet:

Original-Content von: MediGene AG, übermittelt durch news aktuell

Weitere Meldungen: MediGene AG

Das könnte Sie auch interessieren: